Advanced Oncotherapy PLC Notice of Results (7074Z)
21 September 2015 - 4:31PM
UK Regulatory
TIDMAVO
RNS Number : 7074Z
Advanced Oncotherapy PLC
21 September 2015
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Notice of results
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment, will
announce its interim results for the six months ended 30 June 2015
tomorrow, Tuesday 22 September 2015.
Advanced Oncotherapy Plc www.avoplc.com
Sanjeev Pandya, CEO Tel: +44 20 3617 8728
Nicolas Serandour, CFO
Westhouse Securities (Nomad &
Joint Broker)
Antonio Bossi / David Coaten Tel: +44 20 7601 6100
Beaufort Securities (Joint Broker)
Jon Levinson / Elliot Hance Tel: +44 20 7382 8300
Walbrook PR (Financial PR & IR) Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 541 893 / Mob: +44
7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy's team "ADAM" based in Geneva focuses on
the development of a proprietary proton accelerator called Linac
Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons
to the energy levels achieved in legacy machines but in a unit that
is a quarter of the size and between a quarter and a fifth of the
cost. This compact configuration delivers proton beams in a way
that facilitates a greater precision and electronic control which
is not achievable with older technologies.
Advanced Oncotherapy is a provider of particle therapy with
protons that harnesses the best in modern technology. As a result,
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology as well as better health outcomes and lower treatment
related side effects.
The Company has signed a purchase agreement with Sinophi
Healthcare Limited for one LIGHT proton therapy system to be
installed in a hospital in China and has further Letters of Intent
from other healthcare providers.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFMGZLDMGGKZM
(END) Dow Jones Newswires
September 21, 2015 10:31 ET (14:31 GMT)
Carecapital (LSE:CARE)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Carecapital (LSE:CARE)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Carecapital (Londoner Börse): 0 Nachrichtenartikel
Weitere Carecapital News-Artikel